Dyadic International, Inc. (DYAI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Mark A. Emalfarb | Founder, CEO & Director | 841.67k | -- | 1956 |
| Mr. Joseph P. Hazelton | President & COO | 380.81k | -- | 1976 |
| Ms. Ping Wang Rawson CPA, M.B.A. | Chief Financial Officer | 344.83k | -- | 1975 |
| Ms. Ana Gómez Rodriguez | Secretary of the Board | -- | -- | -- |
Dyadic International, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 6
Description
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Corporate Governance
Upcoming Events
August 11, 2025 at 10:59 AM UTC - August 15, 2025 at 12:00 PM UTC
Dyadic International, Inc. Earnings Date
Recent Events
March 31, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission